The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumRecap - In biotech investing, rarely do five trading sessions go by without some explosive volatility. This week, it was Merck’s (MRK) acquistion of Cubist Pharmaceuticals (CBST) for $9 billion, and bluebird … Continue Reading
Read nowResearch - With data for ONT-380 to be presented at SABCS, Oncothyreon (ONTY) announced it has licensed ONT-380 from partner Array Biopharma (ARRY) for $20 million.
PremiumResearch - Bluebird Bio (BLUE) surprised everyone on Monday evening, exceeding expectations for early data from the LentiGlobin drug candidate.
Read nowResearch - Merck is buying Cubist for $102/share, valuing the antibiotics company at $9.5B including its cash. After the close on Monday, the U.S. District Court in Delaware … Continue Reading
PremiumzFree - 2014 has already been a year of M&A records in the biopharmaceutical industry, and on Monday December 8 yet another major transaction occurred, this time … Continue Reading
Read nowResearch - Immune checkpoint regulators are again making headlines, this time at the American Society of Hematology, where they are demonstrating exciting early efficacy in hematological malignancies. … Continue Reading
Read nowRecap - The American Society of Hematology’s annual meeting begins this weekend in San Francisco. It’s a big event for the oncology research community, particularly those studying blood cancers, … Continue Reading
Read now
